Syros Pharmaceuticals (SYRS) and Its Competitors Financial Review
Syros Pharmaceuticals (NASDAQ: SYRS) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it compare to its peers? We will compare Syros Pharmaceuticals to related companies based on the strength of its institutional ownership, valuation, dividends, analyst recommendations, profitability, earnings and risk.
This table compares Syros Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Syros Pharmaceuticals Competitors||-13,404.97%||246.04%||-20.09%|
Earnings & Valuation
This table compares Syros Pharmaceuticals and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Syros Pharmaceuticals||$1.42 million||-$48.99 million||-7.74|
|Syros Pharmaceuticals Competitors||$579.30 million||$241.72 million||-6.68|
Syros Pharmaceuticals’ peers have higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and target prices for Syros Pharmaceuticals and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Syros Pharmaceuticals Competitors||197||915||1698||67||2.57|
Syros Pharmaceuticals currently has a consensus target price of $26.37, suggesting a potential upside of 60.00%. As a group, “Biopharmaceuticals” companies have a potential upside of 6.84%. Given Syros Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Syros Pharmaceuticals is more favorable than its peers.
Institutional & Insider Ownership
59.6% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 33.6% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Syros Pharmaceuticals has a beta of -3.79, indicating that its share price is 479% less volatile than the S&P 500. Comparatively, Syros Pharmaceuticals’ peers have a beta of 1.28, indicating that their average share price is 28% more volatile than the S&P 500.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.
Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.